Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Chia Tai broadens its biparatopic breast cancer approach
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
Concentra picks up a new Cargo
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
